Except he was talking about unique approach in JAKi space. Instead of picking one drug for all indications like $GILD $GLPG filgotinib $ABBV upadacitinib, $PFE pick different JAKi for different indications, 1 for skin, 1 for arthritis, 1 for gut, best in class in each indication. https://t.co/Qua6oEhC2B